International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial.
Tailoring treatment by patient strata based on the risk of disease progression and treatment toxicity might improve outcomes of patients with posttransplant lymphoproliferative disorder (PTLD). We analysed the cohort of 70 patients treated in the international, multicenter phase II PTLD-1 trial (NCT01458548) to identify such factors. Of the previously published scoring systems in PTLD, the international prognostic index (IPI), the PTLD prognostic index and the Ghobrial score were predictive for overall survival. None of the scoring systems had a considerable effect on the risk for disease progression. Age and ECOG performance status were the baseline variables with the highest prognostic impact in the different scoring systems. Baseline variables not included in the scoring systems that had an impact on overall survival and disease progression were the type of transplant and the response to rituximab at interim staging. Thoracic organ transplant recipients who did not respond to rituximab monotherapy were at particularly high risk for death from disease progression with subsequent CHOP-based chemotherapy. Patients in complete remission after four courses of rituximab and patients in partial remission with low-risk IPI had a low risk of disease progression. We speculate that chemotherapy might not be necessary in this patient cohort.
Department of Internal Medicine II: Hematology and Oncology, University Medical Centre Schleswig-Holstein, Campus Kiel, Kiel, Germany; Department of Hematology, Oncology and Tumor Immunology Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany.
R U
RU
Trappe
S
S
Choquet
D
D
Dierickx
P
P
Mollee
J M
JM
Zaucha
M H
MH
Dreyling
U
U
Dührsen
C
C
Tarella
O
O
Shpilberg
M
M
Sender
G
G
Salles
F
F
Morschhauser
A
A
Jaccard
T
T
Lamy
P
P
Reinke
R
R
Neuhaus
H
H
Lehmkuhl
H A
HA
Horst
M
M
Leithäuser
P
P
Schlattmann
I
I
Anagnostopoulos
M
M
Raphael
H
H
Riess
V
V
Leblond
S
S
Oertel
D018951:Antigens, CD20 / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology*; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D008875:Middle Aged; D011379:Prognosis; D000069283:Rituximab / Q000627:therapeutic use*
D018951:Antigens, CD20; D000069283:Rituximab
cancer/malignancy; clinical research/practice; heart transplantation/cardiology; hematology/oncology; immunosuppression/immune modulation; neoplasia: hematogenous/leukemia/lymphoma; posttransplant lymphoproliferative disorder (PTLD)